Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis
November 04, 2021 08:15 ET
|
Processa Pharmaceuticals, Inc.
Next Generation Capecitabine inhibited DPD activity 24-48 hours after PCS6422 administration with < 10% of 5-FU metabolized to FBAL compared to 80% reported for FDA approved capecitabine.24-48...